Legal & General Group PLC Kinnate Biopharma Inc. Transaction History

Legal & General Group PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$9.86 - $15.76 $3,401 - $5,437	345 Added 13.88%	2,831 $34,000
Q2 2022 Aug 22, 2022	SELL	$7.43 - $13.0 $12,920 - $22,607	-1,739 Reduced 41.16%	2,486 $31,000
Q3 2021 Nov 15, 2021	BUY	$17.81 - $24.87 $55,246 - $77,146	3,102 Added 276.22%	4,225 $97,000
Q2 2021 Aug 12, 2021	SELL	$22.19 - $31.55 $5,480 - $7,792	-247 Reduced 18.03%	1,123 $26,000
Q1 2021 May 17, 2021	BUY	$26.99 - $40.0 $36,976 - $54,800	1,370 New	1,370 $42,000

32.9M

94.7K

802K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.